Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Long Analysis Plan



    Scope check: no supplied evidence addresses viral clearance

    The requested topic β€” CB-5083 effects on viral clearance β€” is not supported by any of the seven supplied claim-level records. None report viral titers, antiviral assays, or infection models. Meta-analysis of that claim is therefore impossible from these sources; proceeding anyway would confabulate. What the records do support is a rigorous critique of CB-5083's cellular toxicity and resistance profile, which is a prerequisite for any clearance-based use case.

    1. Rescue vs. resistance: the same compound, opposite phenotypes

    In patient-derived iPSC motor neurons (p97 R155H/+), 400 nM CB-5083 for 6 days rescued neuron survival and restored dysregulated proteome levels toward wild-type β€” but with only 3 biological replicates per group, a single patient line, and one mutation (R155H), limiting generality .

    Conversely, sustained CB-5083 pressure in OVSAHO ovarian cancer cells selected resistant populations with 5.3–5.7-fold higher GI50, driven by D1–D2 linker mutations (E470K/E470D) that raise ATPase activity 3.4–5.8-fold and shift inhibitor IC50s (CB-5083 ~3.4–3.8-fold, ML240 ~15-fold, NMS-873 ~2.6–2.9-fold less active) β€” a resistance mechanism inferred from docking, not co-crystal validation .

    Blue = resistance GI50 (cancer cells); red = ATPase activity of E470 mutants (purified protein); grey = IC50 shifts for inhibitor potency. Midpoint values used where ranges (3.4–3.8, 2.6–2.9) were reported.

    2. Toxicity-relevant mechanism: S-phase replication stress

    Acute p97/Ufd1-NPL4 disruption in S phase causes chromatin-bound cohesin (RAD21) accumulation, reduced BrdU incorporation, Ξ³H2AX-driven replication-associated DNA damage β€” suppressed by aphidicolin and NIPBL depletion. CB-5083 (5 Β΅M, 4 h) reproduced this phenotype, establishing a cell-cycle-specific toxicity pathway that any viral-clearance application in proliferating cells would need to account for .

    3. Why a meta-analysis cannot be built here

    • Missing endpoint: zero records quantify viral clearance (no viral load, no infection model, no host-pathogen outcome).
    • Heterogeneous systems: iPSC motor neurons, ovarian cancer lines, HeLa, SH-SY5Y, and purified protein β€” no common denominator for pooled effect sizes.
    • Known unknowns: does the E470 resistance axis exist in the host cell type of interest? Long-term (>6 day) toxicity in neurons was not assessed. Docking-predicted binding was never co-crystal validated.

    Confidence: high that the viral-clearance claim is unsupported; moderate that the toxicity/resistance characterization is robust (preclinical, small n, single-cell-line selection in places).



    Feedback:    

    Updated: November 17, 2026

     Top Data Sources ExportMCP



     Analysis Wizard



    Aggregating reported fold-change values from the supplied CB-5083 resistance and rescue records to compute effect-size ranges and highlight dose-window constraints for safe inhibition.



     Hypothesis Graveyard



    CB-5083 resistance arises from drug-efflux transporters: falsified in the supplied record β€” sequencing revealed VCP E470 mutations plus second-allele truncation, not pump upregulation, as the resistance mechanism.


    p97 inhibition toxicity is purely proteasome-accumulation-driven: the Ufd1-degradation record shows a distinct S-phase cohesin-extraction/DNA-damage mechanism independent of general proteostasis failure.

     Science Art


    Best Evidence: Meta-analysis VCP/p97 CB-5083 viral clearance toxicity Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT